Correction to: Measuring disease activity in COPD: is clinically important deterioration the answer?
Guardado en:
Autores principales: | Dave Singh, Gerard J. Criner, Ian Naya, Paul W. Jones, Lee Tombs, David A. Lipson, MeiLan K. Han |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bc18cf0abc8049578a93e19a591e367f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD
por: Anthony D’Urzo, et al.
Publicado: (2017) -
Mepolizumab and COPD in Real Life
por: Fernando Revuelta-Salgado, et al.
Publicado: (2022) -
Stage 1 development of a patient-reported experience measure (PREM) for chronic obstructive pulmonary disease (COPD)
por: Susan Walker, et al.
Publicado: (2017) -
Blood Eosinophils and Pulmonary Rehabilitation in COPD
por: Jafar Aljazeeri, et al.
Publicado: (2021) -
Towards precision in defining COPD exacerbations
por: Christine R. Jenkins
Publicado: (2021)